



Accepted but uncorrected

## Syntheses and analytical characterizations of N-alkyl-arylcylohexylamines

Journal:	<i>Drug Testing and Analysis</i>
Manuscript ID:	DTA-15-0185.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Wallach, Jason; University of the Sciences, Department of Pharmaceutical Sciences Colestock, Tristan; University of the Sciences, Department of Pharmaceutical Sciences Cicali, Brian; University of the Sciences, Department of Pharmaceutical Sciences Elliott, Simon; ROAR Rorensics, Kavanagh, Pierce; School of Medicine, Trinity Centre for Health Sciences, St. James Hospital, Department of Pharmacology and Therapeutics Adejare, Adeboye; University of the Sciences, Department of Pharmaceutical Sciences Dempster, Nicola; Liverpool John Moores University, School of Pharmacy and Biomolecular Sciences Brandt, Simon; School of Pharmacy & Biomolecular Sciences , Liverpool John Moores University
Keywords:	New psychoactive substances, Research chemicals, Phencyclidine, NMDA receptors, Arylcyclohexylamines
Abstract:	The rise in new psychoactive substances that are available as 'research chemicals' (RCs) remains a significant forensic and legislative challenge. A number of arylcyclohexylamines have attracted attention as RCs and continued to be encountered, including 3-MeO-PCP, 3-MeO-PCE and 3-MeO-PCPr. These compounds are commonly perceived as ketamine-like dissociative substances and are believed to act predominantly via antagonism of the N-methyl-D-aspartate (NMDA) receptor. To aid in the identification of newly emerging substances the syntheses of fifteen N-alkyl-arylcylohexylamines are described. Analytical characterizations were performed via gas chromatography and high performance liquid chromatography coupled to multiple forms of mass spectrometry as well as nuclear magnetic resonance spectroscopy, ultraviolet diode array detection and infrared spectroscopy. The series consisted of the N-alkyl derivatives (N-methyl, N-ethyl, N-propyl) of phenyl-substituted and isomeric 2-, 3- and 4-methoxy phenylcyclohexylamines, as well as the N-alkyl derivatives obtained from a 3-methylphenyl and 2-thienyl moiety. In addition to the presentation of a range of previously unreported data, it was also found that positional isomers of aryl methoxyl-substituted arylcyclohexylamines were readily distinguishable under a variety of analytical conditions.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SCHOLARONE™  
Manuscripts

For Peer Review

## Syntheses and analytical characterizations of *N*-alkyl-arylcylohexylamines

Jason Wallach <sup>a</sup>, Tristan Colestock <sup>a</sup>, Brian Cicali <sup>a</sup>, Simon P. Elliott <sup>b</sup>, Pierce V. Kavanagh <sup>c</sup>, Adeboye Adejare <sup>a</sup>, Nicola M. Dempster <sup>d</sup>, Simon D. Brandt <sup>d,\*</sup>

<sup>a</sup> *Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA 19104, USA*

<sup>b</sup> *ROAR Forensics, Malvern Hills Science Park, Geraldine Road, WR14 3SZ, UK*

<sup>c</sup> *Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James Hospital, Dublin 8, Ireland*

<sup>d</sup> *School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK*

\*Correspondence to: Simon D. Brandt, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. E-Mail: s.brandt@ljmu.ac.uk

**Running title:** Characterization of *N*-alkyl-arylcylohexylamines

### Abstract

The rise in new psychoactive substances that are available as 'research chemicals' (RCs) remains a significant forensic and legislative challenge. A number of arylcylohexylamines have attracted attention as RCs and continued to be encountered, including 3-MeO-PCP, 3-MeO-PCE and 3-MeO-PCPr. These compounds are commonly perceived as ketamine-like dissociative substances and are believed to act predominantly via antagonism of the *N*-methyl-D-aspartate (NMDA) receptor. To aid in the identification of newly emerging substances the syntheses of fifteen *N*-alkyl-arylcylohexylamines are described. Analytical characterizations were performed via gas chromatography and high performance liquid chromatography coupled to multiple forms of mass spectrometry as well as nuclear magnetic resonance spectroscopy, ultraviolet diode array detection and infrared spectroscopy. The series consisted of the *N*-alkyl derivatives (*N*-methyl, *N*-ethyl, *N*-propyl) of phenyl-substituted and isomeric 2-, 3- and 4-methoxy phenylcylohexylamines, as well as the *N*-alkyl derivatives obtained from a 3-methylphenyl and 2-thienyl moiety. In addition to the presentation of a range of previously unreported data, it was also found that positional isomers of aryl methoxyl-substituted arylcylohexylamines were readily distinguishable under a variety of analytical conditions.

**Keywords:** New psychoactive substances; 'research chemicals'; phencyclidine; NMDA receptors; arylcyclohexylamines

## Introduction

The non-medical use of dissociative drugs including 1-(1-phenylcyclohexyl)piperidine (PCP), ketamine and their derivatives is a challenge to policy makers, clinicians and forensic investigators charged with their identification. More recent examples of dissociative drugs include 'research chemicals' (RCs) such as 3-MeO-PCP, methoxetamine (MXE), diphenidine and 2-methoxydiphenidine (2-MXP).<sup>[1-4]</sup> In the UK, a range of arylcyclohexylamines were placed under control in 2013 following generic legislation<sup>[5]</sup> but control status varies across the globe. Within one week of introducing generic control, diphenidine was available for purchase in the UK, which added to the existing product catalogues of substances suspected to show dissociative properties in humans.<sup>[1]</sup> The association of some of those newly emerging substances with acute toxicity<sup>[6-8]</sup> serves as a reminder that the accurate identification of these substances is essential for the monitoring of new psychoactive substances.<sup>[9,10]</sup>

The major pharmacological mechanism that appears to mediate a significant portion of the therapeutically relevant and psychoactive effects of dissociative substances includes uncompetitive antagonism of the *N*-methyl-D-aspartate (NMDA) receptor. NMDA receptor antagonists exemplify an important pharmacological class that provides promising pharmacological tools. They are used or are being investigated in a number of therapeutic areas including general anesthetics, neuroprotection, management of neuropathic pain and depression.<sup>[1,11,12]</sup> Issues linked with clinical tolerability remain challenging for clinical development of this promising pharmacological class.<sup>[1,13,14]</sup>

Recently a study of the receptor binding profiles of a series of dissociative legal highs included 3-methoxyeticyclidine (3-MeO-PCE) (**3b**).<sup>[15]</sup> Consistent with reports of its potent dissociative effects in humans<sup>[1]</sup> it showed high affinity for (+)-[<sup>3</sup>H]MK-801 labeled NMDA receptors (61 nM). In addition, affinity for the serotonin transporter (115 nM) and lesser affinity at sigma-1 and sigma-2 receptor sites were observed.<sup>[15]</sup> It is unknown how these additional pharmacological interactions may contribute to the psychoactive properties of 3-MeO-PCE and related arylcyclohexylamines and further studies are warranted to explore polypharmacological mechanisms that may be relevant as well.

*N*-Alkyl-aryl-cyclohexylamines including PCE, PCPr and PCiP (Figure 1) were sold on 'street markets' during the 1960-1990s in the United States and PCE in particular enjoyed a large distribution relative to other PCP derivatives.<sup>[1]</sup> Furthermore, a number of *N*-alkoxyalkyl secondary amine derivatives were detected in Germany during the 1990s and included PCMEA, PCEEA, PCMPA and PCEPA (Figure 1), respectively.<sup>[16-18]</sup> More recently, 3-MeO-PCE (**3b**)<sup>[19]</sup> and 3-MeO-PCPr (**3c**) have been sold through Internet based vendors (Figure 1).<sup>[1,20]</sup> Several closely related compounds included derivatives of ketamine, such as methoxetamine, 2-MeO-2-

1  
2  
3 deschloroketamine ('2-MeO-ketamine', 2-MK) and *N*-ethylorketamine ('*N*-ethyl-  
4 ketamine', N-EK) (Figure 1) were previously reported.<sup>[1,19,21]</sup> The analytical  
5 characterizations of a series of tertiary amine based arylcyclohexylamines including  
6 'research chemicals' 3-MeO- and 4-MeO-PCP was previously reported.<sup>[4]</sup> Although a  
7 previous publication described the appearance of 3-MeO-PCE,<sup>[20]</sup> detailed  
8 information on analytical profiles of the secondary amine *N*-alkyl-  
9 arylcyclohexylamines are lacking.  
10

11  
12 This study presents the syntheses of 15 *N*-alkyl-aryl-cyclohexylamines (**1a**) – (**5c**)  
13 using facile routes that are easily adaptable to forensic laboratories. The series  
14 included the *N*-alkyl derivatives (*N*-methyl, *N*-ethyl, *N*-propyl) of 2-, 3- and 4-MeO-  
15 arylcyclohexylamine isomers as well as 3-methylphenyl and 2-thienyl compounds  
16 (Figure 2A). The comprehensive analytical characterizations included the  
17 differentiation between positional isomers of aryl methoxyl-substituted  
18 arylcyclohexylamines.  
19  
20  
21  
22

## 23 Experimental

### 24 Materials

25  
26 All starting materials, reagents and solvents used for synthesis ( $\geq 96\%$ ) were  
27 obtained from Sigma-Aldrich (St. Louis, USA). Column chromatography was  
28 conducted using Merck silica gel, grade 9385 (230-400 mesh, 60 Å). Melting point  
29 ranges were obtained using a DigiMelt A160 SRS melting point apparatus (Stanford  
30 Research Systems, Sunnyvale, USA) at a ramp rate of 2 °C/min.  
31  
32  
33  
34

### 35 Synthesis procedures

36 A representative example is shown for the preparations of (**1a**) – (**1c**), where the  
37 appropriately substituted Grignard reagent served as the starting point (Figure 2B).  
38 NMR data for compounds (**1a**) – (**5c**) are provided in Tables 1–6. NMR data of the  
39 primary amines are shown as supplementary information.  
40  
41

#### 42 Preparation of 1-(thiophen-2-yl)cyclohexan-1-amine (TCA)

43  
44 A solution containing the desired Grignard reagent was prepared consisting of 2-  
45 bromothiophene (147 mmol, 24.08 g) in 200 mL dry THF containing freshly crushed  
46 Mg (442 mmol, 10.75 g) at room temperature under argon. After stirring for 12 hours  
47 at room temperature, cyclohexanone (114 mmol, 11.14 g) was added slowly. The  
48 exothermic reaction mixture was then stirred for an additional 24 hours at which point  
49 it was quenched with 300 mL distilled water (dH<sub>2</sub>O), titrated to pH 7 with a saturated  
50 NH<sub>4</sub>Cl solution and extracted with ethyl acetate (3 x 100 mL). Organic phases were  
51 pooled, washed with a saturated sodium bisulfite solution (2 x 150 mL), saline (1 x  
52 150 mL), dried with anhydrous sodium sulfate and concentrated under reduced  
53 pressure to give 1-(thiophene-2-yl)cyclohexane-1-ol as an amber oil.  
54  
55  
56

57 A solution of the crude tertiary alcohol (104 mmol, 18.94 g) in CHCl<sub>3</sub> (50 mL) was  
58 added dropwise to a vigorously stirred suspension of NaN<sub>3</sub> (208 mmol, 13.51 g) and  
59  
60

1  
2  
3 trifluoroacetic acid (312 mmol, 23.86 mL) in  $\text{CHCl}_3$  (200 mL) at 0 °C under argon.  
4 After addition, the suspension was allowed to recover to room temperature and stir  
5 for 24 hours at which point it had set to a solid mass. The reaction mixture was  
6 carefully quenched by slow addition to a stirred concentrated aqueous solution of  
7  $\text{NaHCO}_3$ . Once the evolution of gas was complete, the organic phase was collected,  
8 washed with  $\text{dH}_2\text{O}$  and saline, dried with anhydrous sodium sulfate and concentrated  
9 under reduced pressure to give the crude azide as a yellow oil. The azide was  
10 purified using flash column chromatography on silica gel with hexanes as the mobile  
11 phase. Early fractions containing the azide product were pooled and concentrated to  
12 produce a light yellow oil (81 mmol, 16.71 g, 77.9% yield).  
13  
14

15  
16 A solution of the purified azide (81 mmol, 16.71 g) in dry THF (50 mL) was added  
17 dropwise over the course of an hour to a vigorously stirred suspension of  $\text{LiAlH}_4$  (242  
18 mmol, 9.2 g) in dry THF (200 mL) under argon at 0°C. The reaction mixture was kept  
19 at 0 °C for 1 h. It was then quenched by cautious dropwise addition of a 50:50  
20 mixture of THF and ice cold  $\text{dH}_2\text{O}$  (50 mL). A few mL of aqueous KOH were added to  
21 ensure a basic pH and ethyl acetate (300 mL) was added and the suspension gravity  
22 filtered to remove insoluble inorganic salts. Inorganic salts were washed with ethyl  
23 acetate. The organic phase was extracted with aqueous HCl solution (3 x 200 mL),  
24 acidic phases pooled, made basic to pH > 12 with KOH pellets and extracted with  
25 ethyl acetate (3 x 70 mL). Organic phases were pooled, washed with saline, dried  
26 with anhydrous magnesium sulfate, gravity filtered and concentrated under reduced  
27 pressure to give a colorless oil. The crude product was purified by flash column  
28 chromatography on silica gel eluting with hexanes:ethyl acetate (3:1) containing  
29 0.5 % triethylamine with a gradually increasing ethyl acetate concentration to 50%.  
30 Desired fractions were pooled and concentrated under reduced pressure to give 1-  
31 (thiophene-2-yl)cyclohexane-1-amine (TCA), a light yellow oil (71 mmol, 12.85 g,  
32 87.7% yield).  
33  
34  
35  
36

37 The HCl salt of TCA was prepared by dissolving it in ethanol, titrating to pH 1.0 with  
38 concentrated HCl, and evaporating under a stream of warm air. Dry acetone (4 Å  
39 sieves) was added in 10 mL increments until all residual moisture and HCl was  
40 removed. The resulting solid was washed with ethyl acetate (2 x 5 mL), dried, and  
41 crystallized by dissolving in a minimal amount of warm methanol diluted with a 10-  
42 fold excess of diethyl ether. The solution was stored at 0 °C overnight. The resulting  
43 crystals were collected by decanting the solvent off and then washing with ethyl  
44 acetate (2 x 5 mL), followed by drying in an oven at 60 °C. The solids were  
45 recrystallized two more times as described to produce white fluffy thin needle-like  
46 crystalline solids (m.p. 214.3 – 215.6 °C).  
47  
48

#### 49 *Preparation of N-methyl-1-(thiophen-2-yl)cyclohexan-1-amine (TCMe) (1a)*

50  
51  
52 A solution of TCA (7.72 mmol, 1.40 g) and ethyl formate (10 mL) containing 4 Å  
53 molecular sieves (1.0 g) were refluxed under an inert atmosphere of argon. As  
54 solvent tended to dissipate, additional ethyl formate was added as needed to keep a  
55 constant volume. After ~72 h the reaction mixture was quenched by diluting in 400  
56 mL 1N aqueous HCl solution. This solution was extracted with ethyl acetate (3 x 60  
57 mL), organic phases pooled, washed with 2N aqueous HCl solution (2 x 100 mL),  
58  
59  
60

1  
2  
3 saline (40 mL), dried and concentrated under vacuum to give *N*-[1-(thiophen-2-yl)cyclohexyl]formamide (*N*-formyl-TCA) as a white solid (6.69 mmol, 1.40 g, 86.7 %  
4 yield). The solid was crystallized from hexanes containing 10% ethyl acetate followed  
5 by storage at 0 °C. However, the crude product was sufficient for use in the  
6 subsequent reaction.  
7  
8

9  
10 A solution of dry THF (40 mL) containing *N*-formyl-TCA (6.69 mmol, 1.40 g) was  
11 added dropwise to a stirred suspension of LiAlH<sub>4</sub> (21.4 mmol, 0.8117 g) in THF (100  
12 mL) at 0 °C under argon. The stirred reaction mixture was then allowed to warm to  
13 room temperature and placed on a mild reflux while maintaining an inert argon  
14 atmosphere. Once complete (TLC or GC/MS), the reaction mixture was placed on ice  
15 and quenched by dropwise addition of a 50:50 mixture of ice cold THF and dH<sub>2</sub>O with  
16 vigorous stirring. The suspension was then diluted with 400 mL ethyl acetate and the  
17 inorganic salts removed by gravity filtration. The filtered inorganic material was  
18 washed heavily with ethyl acetate, and the washings combined and extracted with  
19 aqueous 1N HCl (3 x 200 mL). The pooled aqueous phases were then basified to  
20 >pH 12 with KOH pellets and extracted with ethyl acetate (3 x 60 mL). The pooled  
21 organic extractions were washed with saline, dried with anhydrous magnesium  
22 sulfate and concentrated under reduced pressure to give an amber oil. The crude  
23 product was purified using flash column chromatography on silica gel eluting with  
24 hexanes:ethyl acetate (4:1) containing 1% triethylamine. Desired fractions were  
25 pooled and concentrated yielding colorless TCMe oil (4.92 mmol, 960 mg, 73.5 %  
26 yield). HCl salt prepared as described to give a colorless needle-like crystalline solid  
27 (148 – 149 °C (phase transition), m.p. 194.8 – 195.9 °C). HR-ESI-MS: observed *m/z*  
28 196.11553 (theory [M + H]<sup>+</sup>: C<sub>11</sub>H<sub>18</sub>NS<sup>+</sup> *m/z* 196.11545).  
29  
30  
31  
32

#### 33 *Preparation of N-ethyl-1-(thiophen-2-yl)cyclohexane-1-amine (TCE) (1b)*

34  
35  
36 TCA (5.52 mmol, 1.0 g) was dissolved in triethylamine (1 mL) in a beaker and placed  
37 on ice. Under a blanket of argon gas, acetyl chloride (11.1 mmol, 0.79 mL) was  
38 added dropwise and mixed with a spatula until a waxy white precipitate formed. The  
39 solid was suspended in aqueous 2N HCl solution (100 mL) and extracted with ethyl  
40 acetate (3 x 75 mL). The pooled organic phases were washed with 2N aqueous HCl  
41 solution (2 x 30 mL), dH<sub>2</sub>O (20 mL) and saline (10 mL). The organic solution was  
42 dried with anhydrous sodium sulfate and concentrated under reduced pressure to  
43 produce *N*-[1-(thiophene-2-yl)cyclohexyl]acetamide (4.92 mmol, 1.10 g, 89.5 % yield).  
44 These crystals were recrystallized from boiling ethyl acetate and stored at 0 °C. The  
45 crude product was sufficient in purity for use in the subsequent reaction.  
46  
47

48  
49 A solution of *N*-[1-(thiophene-2-yl)cyclohexyl]acetamide (4.5 mmol, 1.0 g) in dry THF  
50 (20 mL) was added dropwise to a stirred suspension of LiAlH<sub>4</sub> (13.4 mmol, 0.51 g) in  
51 dry THF (100 mL) on ice under argon. Upon completion of the addition, the reaction  
52 mixture was removed from ice and brought to a mild reflux. The reflux was continued  
53 and monitored for completion by TLC (~ 4 h). The reaction mixture was quenched  
54 with dropwise addition of a 50:50 mixture of ice cold THF and dH<sub>2</sub>O. A few drops of  
55 KOH solution were added and the reaction mixture diluted with ethyl acetate (200  
56 mL). The resulting inorganic salts were removed via gravity filtration and washed with  
57 ethyl acetate (150 mL). The organic phase was extracted with aqueous 1N HCl  
58  
59  
60

1  
2  
3 solution (3 x 75 mL). The pooled aqueous phases were made basic with KOH pellets  
4 (pH >12) and extracted with ethyl acetate (3 x 100 mL). The pooled organic fractions  
5 were washed with saline (20 mL), dried with anhydrous magnesium sulfate, gravity  
6 filtered and concentrated under reduced pressure to produce *N*-ethyl-1-(thiophene-2-  
7 yl)cyclohexane-1-amine (**1b**) (2.10 mmol, 0.45 g, 46.7 % yield). HCl salt prepared as  
8 previously described to give a colorless needle-like crystalline solid (m.p. 193.9 –  
9 195.1 °C; lit: 195-196 °C<sup>[22]</sup>) HR-ESI-MS: observed *m/z* 210.13120 (theory [M + H]<sup>+</sup>:  
10 C<sub>12</sub>H<sub>20</sub>NS<sup>+</sup> *m/z* 210.13110).  
11

#### 12 13 *Preparation of N-propyl-1-(thiophen-2-yl)cyclohexane-1-amine (TCPr) (1c)*

14  
15  
16 TCPr was prepared as described for TCE above in 92% yield from TCA (5.52 mmol,  
17 1.0 g) as a white crystalline solid. Generation of the HCl salt gave a colorless needle-  
18 like crystalline solid (116 – 117 °C (phase transition), m.p. 183.8 – 185.5 °C). HR-  
19 ESI-MS: observed *m/z* 224.1465 (theory [M + H]<sup>+</sup>: C<sub>13</sub>H<sub>22</sub>NS<sup>+</sup> *m/z* 224.1467).  
20

#### 21 22 *Preparation of 1-(2-methoxyphenyl)cyclohexan-1-amine (2-MeO-PCA)*

23  
24 2-MeO-PCA was prepared in 54.8% yield from cyclohexanone (26.6 mmol, 2.61 g)  
25 and 2-bromoanisole (31.9 mmol, 5.96 g) as described for TCA above. The HCl salt  
26 was prepared as described for 3-MeO-PCA to give colorless needles with a melting  
27 point of 176.7 – 178.0 °C (lit: 212-215 °C<sup>[23]</sup>).  
28

#### 29 30 *Preparation of N-methyl-1-(2-methoxyphenyl)cyclohexan-1-amine (2-MeO-PCMe) (2a)*

31  
32  
33 *N*-[1-(2-methoxyphenyl)cyclohexyl]formamide (*N*-formyl-2-MeO-PCA) was prepared  
34 as previously described in 67.7 % yield from 2-MeO-PCA (5.21 mmol, 1.07 g) as a  
35 white solid. 2-MeO-PCMe was obtained as described in 16.9% yield from *N*-formyl-2-  
36 MeO-PCA (0.86 mmol, 0.20 g), as a colorless oil. The HCl salt was obtained as a  
37 white crystalline solid; 107 – 110 °C (phase transition), m.p. 185 – 187 °C. HR-ESI-  
38 MS: observed *m/z* 220.16982 (theory [M + H]<sup>+</sup>: C<sub>14</sub>H<sub>22</sub>NO<sup>+</sup> *m/z* 220.16959).  
39  
40

#### 41 42 *Preparation of N-ethyl-1-(2-methoxyphenyl)cyclohexan-1-amine (2-MeO-PCE) (2b)*

43  
44  
45 *N*-[1-(2-methoxyphenyl)cyclohexyl]acetamide (*N*-acetyl-2-MeO-PCA) was prepared  
46 as previously described in 93.6 % yield from 2-MeO-PCA (5.50 mmol, 1.13 g) as a  
47 white solid. 2-MeO-PCE freebase was prepared as described in 91.2% yield from *N*-  
48 acetyl-2-MeO-PCA (3.92 mmol, 0.97 g) as a colorless oil. The sparkling white  
49 crystalline HCl salt gave a m.p. of 194.3 – 195.9 °C. HR-ESI-MS: observed *m/z*  
50 234.18520 (theory [M + H]<sup>+</sup>: C<sub>15</sub>H<sub>24</sub>NO<sup>+</sup> *m/z* 234.18524).  
51

#### 52 53 *Preparation of N-propyl-1-(2-methoxyphenyl)cyclohexan-1-amine (2-MeO-PCPr) (2c)*

54  
55  
56 *N*-[1-(2-methoxyphenyl)cyclohexyl]propanamide (*N*-propionyl-2-MeO-PCA) was  
57 prepared as previously described in 88.0 % yield from 2-MeO-PCA (5.41 mmol, 1.11  
58 g) as a white solid. 2-MeO-PCPr was prepared as described in 28.9% yield from *N*-  
59  
60



propionyl-2-MeO-PCA (1.34 mmol, 0.35 g), as a colorless oil. The HCl salt was a sparkling white crystalline solid (m.p. 213.5 – 214.5 °C). HR-ESI-MS: observed  $m/z$  248.20086 (theory  $[M + H]^+$ :  $C_{16}H_{26}NO^+$   $m/z$  248.20089).

#### *Preparation of 1-(3-methoxyphenyl)cyclohexan-1-amine (3-MeO-PCA)*

3-MeO-PCA was prepared in 61.0% yield from cyclohexanone (53.0 mmol, 5.23 g) and 3-bromoanisole (64.0 mmol, 11.97 g). The HCl salt of 3-MeO-PCA was prepared as described previously (m.p. 197.0 – 197.7 °C<sup>[4]</sup>; lit: 195 – 196 °C<sup>[23]</sup>).

#### *Preparation of N-methyl-1-(3-methoxyphenyl)cyclohexan-1-amine (3-MeO-PCMe) (3a)*

*N*-[1-(3-methoxyphenyl)cyclohexyl]formamide (*N*-formyl-3-MeO-PCA) was prepared as previously described in 97.0% yield from 3-MeO-PCA (10.2 mmol, 2.10 g) as a white solid. 3-MeO-PCMe was prepared as described in 79.0% yield from *N*-formyl-3-MeO-PCA (9.94 mmol, 2.32 g), as colorless oil. The HCl salt of 3-MeO-PCMe (**3a**) was prepared and recrystallized twice from methanol/diethyl ether at 0 °C to give a colorless, crystalline solid (m.p. 214.5 – 217.0 °C). HR-ESI-MS: observed  $m/z$  220.16948 (theory  $[M + H]^+$ :  $C_{14}H_{22}NO^+$   $m/z$  220.16959).

#### *Preparation of N-ethyl-1-(3-methoxyphenyl)cyclohexan-1-amine (3-MeO-PCE) (3b)*

*N*-[1-(3-methoxyphenyl)cyclohexyl]acetamide (*N*-acetyl-3-MeO-PCA) was prepared as previously described in 99.1% yield from 3-MeO-PCA (6.33 mmol, 1.30 g) as a deep orange oil. 3-MeO-PCE prepared in 55.3% yield as described from *N*-acetyl-3-MeO-PCA (1.82 mmol, 0.45 g). HCl salt was prepared to give a white crystalline solid, m.p. 214.0 – 215.5 °C. HR-ESI-MS: observed  $m/z$  234.18519 (theory  $[M + H]^+$ :  $C_{15}H_{24}NO^+$   $m/z$  234.18524).

#### *Preparation of N-propyl-1-(3-methoxyphenyl)cyclohexan-1-amine (3-MeO-PCPr) (3c)*

*N*-[1-(3-methoxyphenyl)cyclohexyl]propanamide (*N*-propionyl-3-MeO-PCA) was prepared as previously described in 91.0% yield from 3-MeO-PCA (6.33 mmol, 1.30 g) as an orange colored oil. 3-MeO-PCPr prepared as described in 75.5% yield from *N*-propionyl-3-MeO-PCA (3.82 mmol, 1.0 g) as a colorless oil. HCl salt was prepared as described to give a white crystalline solid, m.p. 181.0 – 183.0 °C. HR-ESI-MS: observed  $m/z$  248.20063 (theory  $[M + H]^+$ :  $C_{16}H_{26}NO^+$   $m/z$  248.20089).

#### *Preparation of 1-(4-methoxyphenyl)cyclohexan-1-amine (4-MeO-PCA)*

4-MeO-PCA was prepared as previously described in 49.0% yield from cyclohexanone (41.5 mmol, 4.07 g) and 4-bromoanisole (49.7 mmol, 9.30 g) as colorless oil. HCl salt was prepared to give a thin needle-like crystalline solid, m.p. 251.1 – 252.0 °C (Lit: 233 – 234 °C<sup>[23]</sup>)

1  
2  
3 *Preparation of N-methyl-1-(4-methoxyphenyl)cyclohexan-1-amine (4-MeO-PCMe)*  
4 **(4a)**

5  
6 *N*-[1-(4-methoxyphenyl)cyclohexyl]formamide (*N*-formyl-4-MeO-PCA) was prepared  
7 as previously described in 87.0 % yield from 4-MeO-PCA (5.16 mmol, 1.06 g) as a  
8 white solid. 4-MeO-PCMe was prepared in 39.5% yield from *N*-formyl-4-MeO-PCA  
9 (3.34 mmol, 0.780 g), as a colorless oil. HCl salt was prepared as described to give a  
10 sparkling colorless needle-like solid, m.p. 164.0 – 165.7 °C. HR-ESI-MS: observed  
11 *m/z* 220.1964 (theory [M + H]<sup>+</sup>: C<sub>14</sub>H<sub>22</sub>NO<sup>+</sup> *m/z* 220.1696).

12  
13  
14  
15 *Preparation of N-ethyl-1-(4-methoxyphenyl)cyclohexan-1-amine (4-MeO-PCE) (4b)*

16  
17 *N*-[1-(4-methoxyphenyl)cyclohexyl]acetamide (*N*-acetyl-4-MeO-PCA) was prepared  
18 as previously described in 90.5 % yield from 4-MeO-PCA (6.92 mmol, 1.42 g) as a  
19 white solid. 4-MeO-PCE was prepared as described in 50.8% yield from *N*-acetyl-4-  
20 MeO-PCA (2.42 mmol, 0.60 g), as a colorless oil. HCl salt was prepared as  
21 described to give a sparkling white crystalline solid, m.p. 189.0 – 191.8 °C. HR-ESI-  
22 MS: observed *m/z* 234.1850 (theory [M + H]<sup>+</sup>: C<sub>15</sub>H<sub>24</sub>NO<sup>+</sup> *m/z* 234.1852).

23  
24  
25  
26 *Preparation of N-propyl-1-(4-methoxyphenyl)cyclohexan-1-amine (4-MeO-PCPr) (4c)*

27  
28 *N*-[1-(4-methoxyphenyl)cyclohexyl]propanamide (*N*-propyl-4-MeO-PCA) was  
29 prepared as previously described in 86.0 % yield from 4-MeO-PCA (6.82 mmol, 1.40  
30 g) as a white solid. 4-MeO-PCPr was prepared as described in 39.4% yield from *N*-  
31 propyl-4-MeO-PCA (2.30 mmol, 0.60 g), as a colorless oil. HCl salt was prepared as  
32 described to give a sparkling white crystalline solid, m.p. 184.8 – 186.3 °C. HR-ESI-  
33 MS: observed *m/z* 248.2006 (theory [M + H]<sup>+</sup>: C<sub>16</sub>H<sub>26</sub>NO<sup>+</sup> *m/z* 248.2009).

34  
35  
36 *Preparation of 1-(3-methylphenyl)cyclohexan-1-amine (3-Me-PCA)*

37  
38 3-Me-PCA was prepared as described in 70.2% yield from cyclohexanone (25.0  
39 mmol, 2.45 g) and 3-bromotoluene (30.0 mmol, 5.13 g) as colorless oil. HCl salt was  
40 prepared to give a white fluffy crystalline solid, m.p. 209 – 212 °C (Lit: 209  
41 – 210 °C<sup>[23]</sup>).

42  
43  
44 *Preparation of N-methyl-1-(3-methylphenyl)cyclohexan-1-amine (3-Me-PCMe) (5a)*

45  
46 *N*-[1-(3-methylphenyl)cyclohexyl]formamide (*N*-formyl-3-Me-PCA) was prepared as  
47 previously described in 95.9% yield from 3-Me-PCA (11.1 mmol, 2.1 g) as a light  
48 yellow oil. 3-Me-PCMe was prepared as described in 59.0% yield from *N*-formyl-3-  
49 Me-PCA (10.6 mmol, 2.31 g), as a colorless oil. HCl salt was prepared to give fluffy  
50 colorless needle-like crystalline solid, m.p. 213.3 – 215.5 °C. HR-ESI-MS: observed  
51 *m/z* 204.17439 (theory [M + H]<sup>+</sup>: C<sub>14</sub>H<sub>22</sub>N<sup>+</sup> *m/z* 204.17468).

52  
53  
54  
55 *Preparation of N-ethyl-1-(3-methylphenyl)cyclohexan-1-amine (3-Me-PCE) (5b)*

1  
2  
3 *N*-[1-(3-methylphenyl)cyclohexyl]acetamide (*N*-acetyl-3-Me-PCA) was prepared as  
4 described in 95.5% yield from 3-Me-PCA (5.28 mmol, 1.0 g) as an orange crystalline  
5 solid. 3-Me-PCE prepared as described in 76.4% yield from *N*-acetyl-3-Me-PCA  
6 (6.48 mmol, 1.50 g), as a colorless oil. HCl salt was prepared to give a white  
7 crystalline solid, m.p. 234.1 – 235.0 °C (Lit: 236 – 237 °C<sup>[24]</sup>). HR-ESI-MS: observed  
8 *m/z* 218.19030 (theory [M + H]<sup>+</sup>: C<sub>15</sub>H<sub>24</sub>N<sup>+</sup> *m/z* 218.19033).

#### 10 11 *Preparation of N-propyl-1-(3-methylphenyl)cyclohexan-1-amine (3-Me-PCPr) (5c)*

12  
13 *N*-[1-(3-methylphenyl)cyclohexyl]propanamide (*N*-propionyl-3-Me-PCA) was  
14 prepared as previously described in 86.5 % yield from 3-Me-PCA (5.28 mmol, 1.0 g)  
15 as a white solid. 3-Me-PCPr was prepared as described in 65.0% yield from *N*-  
16 propionyl-3-Me-PCA (5.30 mmol, 1.30 g), as a colorless oil. HCl salt was prepared to  
17 give a fluffy white crystalline solid, m.p. 226.0 – 226.8 °C. HR-ESI-MS: observed *m/z*  
18 232.20588 (theory [M + H]<sup>+</sup>: C<sub>16</sub>H<sub>26</sub>N<sup>+</sup> *m/z* 232.20598).

### 21 22 **Instrumentation**

#### 23 24 *Nuclear magnetic resonance spectroscopy*

25  
26 <sup>1</sup>H (400 MHz) and <sup>13</sup>C NMR spectra (100 MHz) were obtained from the hydrochloride  
27 salts in CDCl<sub>3</sub> solutions (100% and 99.96% D, 0.03% (v/v) TMS) on a Bruker  
28 Ultrashield 400 plus spectrometer with a 5 mm BBO S1 (Z gradient plus) probe at  
29 24 °C. Internal chemical shift references were TMS (δ = 0.00 ppm) and solvent (δ =  
30 77.0 ppm).

#### 31 32 33 *Gas chromatography ion trap mass spectrometry*

34  
35 Data for all fifteen *N*-alkyl-aryl-cyclohexylamines (0.5 mg/mL in methanol) were  
36 recorded under full can electron (EI) and chemical ionization (CI) conditions using  
37 HPLC grade methanol as the liquid CI reagent. A Varian 450-GC gas chromatograph  
38 coupled to a Varian 220-MS ion trap mass spectrometer and a Varian 8400  
39 autosampler was employed with a Varian CP-1177 injector (275 °C) in split mode  
40 (1:50) (Walnut Creek, CA, USA). The Varian MS Data Review function of the  
41 Workstation software, version 6.91, was used for data acquisition. Transfer line,  
42 manifold and ion trap temperatures were set at 310, 80 and 220 °C, respectively. The  
43 carrier gas was helium at a flow rate of 1 mL/min using the EFC constant flow mode.  
44 The default settings for CI ionization parameters (0.4 s/scan) were used: CI storage  
45 level *m/z* 19.0; ejection amplitude *m/z* 15.0; background mass *m/z* 55; maximum  
46 ionization time 2000 μs; maximum reaction time 40 ms; target TIC 5000 counts. An  
47 Agilent J&W VF-5ms GC column (30 m × 0.25 mm, 0.25 μm) was employed for  
48 separation. The starting temperature was set at 130 °C and held for 1 min. The  
49 temperature then increased at 20 °C/min to 280 °C and held constant for 11.50 min  
50 to give a total run time of 20.00 min.

#### 51 52 53 54 55 56 *Electrospray triple quadrupole mass spectrometry*

1  
2  
3 Electro spray triple quadrupole tandem mass spectrometry experiments were carried  
4 out by direct infusion (10  $\mu$  L/min at 0.01 mg/mL) of (**1a**) – (**5c**) compounds using a  
5 Waters Micromass Quattro Premier triple quadrupole MS/MS system (Waters  
6 Micromass, Manchester, UK) and the Masslynx version 4.1 software. Optimization of  
7 signal intensities were performed in positive MS scan and in product ion scan mode.  
8 The optimized source conditions were as follows: capillary 3.12 kV, rf lens 0.1 V,  
9 source temperature 100 °C, desolvation temperature 200 °C and the multiplier  
10 voltage was 650 V. Nitrogen was used as the cone gas (50 L/h) and desolvation gas  
11 (200 L/h) whilst the collision gas was argon (0.3 mL/min flow). The  $[M + H]^+$  ion  
12 corresponding to all fifteen substances were selected for MS/MS experiments.  
13 Product ions were collected over the range  $m/z$  50 and  $m/z$  250. Scan time for each  
14 channel was 0.5 s and interscan delay was 0.1 s. The cone voltage and collision  
15 energy values were as follows: 10 V and 18 eV for (**1a**) – (**1c**); 18 V and 15 eV for all  
16 three sets of methoxyphenyl substituted isomers; 15 V and 15 eV for (**5a**) and (**5c**)  
17 and 15 V and 12 eV for (**5b**), respectively.  
18  
19  
20  
21

#### 22 *High-resolution electrospray mass spectrometry*

23  
24  
25 Analyses were carried out by characterization using UHPLC-QTOF-MS/MS as  
26 described previously.<sup>[25,26]</sup> Briefly, mobile phases used for UHPLC separation  
27 consisted of 100% acetonitrile (1% formic acid) and an aqueous solution of 1%  
28 formic acid. The column temperature was set at 40 °C (0.6 mL/min) and data were  
29 acquired for 5.5 min. The elution was a 5–70% acetonitrile gradient ramp over 3.5  
30 min, then increased to 95% acetonitrile in 1 min and held for 0.5 min before returning  
31 to 5% acetonitrile in 0.5 min. QTOF-MS data were acquired in positive mode  
32 scanning from  $m/z$  100 –  $m/z$  1000 with and without auto MS/MS fragmentation.  
33 Ionization was achieved with an Agilent JetStream electrospray source and infused  
34 internal reference masses. Agilent 6540 QTOF-MS parameters: gas temperature  
35 325 °C, drying gas 10 L/min and sheath gas temperature 400 °C. Internal reference  
36 ions at  $m/z$  121.05087 and  $m/z$  922.00979 were used.  
37  
38  
39

#### 40 *High performance liquid chromatography diode array detection*

41  
42 HPLC-DAD analyses<sup>[25,26]</sup> were carried out on a Dionex 3000 Ultimate system  
43 coupled to a UV diode array detector (Thermo Fisher, St Albans, UK), using a  
44 Phenomenex Synergi Fusion column (150 mm x 2 mm, 4  $\mu$ m) that was protected by  
45 a 4 mm x 3 mm Phenomenex Synergi Fusion guard column (Phenomenex,  
46 Macclesfield, UK). The mobile phases were made from 70% acetonitrile with 25 mM  
47 TEAP buffer and an aqueous solution of 25 mM TEAP buffer. Elution was achieved  
48 with a gradient that started with 4% acetonitrile and ramped to 70% acetonitrile in 15  
49 min and held for 3 min. The total acquisition time was 18 min at a flow rate of 0.6  
50 mL/min. The diode array detection window was set at 200 nm to 595 nm (collection  
51 rate 2 Hz).  
52  
53  
54

#### 55 *Infrared spectroscopy*

1  
2  
3 Infrared (IR) spectra were obtained on a Perkin Elmer Spectrum BX FTIR model  
4 (Llantrisant, UK) using a Pike MIRacle ATR system. Data were acquired with the  
5 Spectrum v5.01 software (scan range 4000–400 cm<sup>-1</sup>, resolution 4 cm<sup>-1</sup>, 16 scans).  
6  
7

## 8 **Results and discussion**

9  
10 A number of routes exist for the syntheses of arylcyclohexylamines.<sup>[1,27]</sup> In the  
11 present study, primary amines were synthesized using modified Geneste route  
12 (Figure 2B)<sup>[28]</sup>, similar to the approach taken in previous work on PCP and 1-(1-  
13 phenylcyclohexyl)pyrrolidine (PCPy) analogs.<sup>[4]</sup> It has been found in practice that the  
14 primary amines represent practical intermediates to prepare appropriately substituted  
15 secondary and tertiary amines. Secondary amines were synthesized by conversion  
16 to the amide, which was found to be high yielding. Subsequent reduction of the  
17 amide gave the desired *N*-alkyl secondary amines (**1a**) – (**5c**) in moderate to good  
18 yields.  
19  
20

21  
22 The syntheses of primary amine intermediates 3-Me-PCA, 2-MeO-PCA, 3-MeO-PCA,  
23 4-MeO-PCA and TCA have been described previously,<sup>[22,23,29,30]</sup> and these were  
24 based on the implementation of the Geneste route in most cases. A modified imine  
25 (sulfimine) route has been described for 3-MeO-PCA<sup>[31]</sup> and a route via an imine  
26 stage was employed before for the preparation of secondary amine compounds  
27 carrying a 3-methoxyphenyl substituent.<sup>[32]</sup> The preparation of secondary amines  
28 from primary amine intermediates via alkylation with the appropriate alkyl halide was  
29 also reported for TCMc (**1a**), TCE (**1b**) and TCPc (**1c**).<sup>[30,33]</sup> The syntheses of the  
30 methoxy isomers was described in 1988 using an imine route.<sup>[32]</sup>  
31  
32

33  
34 The characterization of a number of compounds appeared to be unreported in the  
35 existing literature, such as 2-MeO-PCE (**2b**), 2-MeO-PCPr (**2c**), 3-Me-PCPr (**5c**), and  
36 4-MeO-PCPr (**4c**). Likewise, 2-MeO-PCMe (**2a**) and 4-MeO-PCMe (**4a**) do not  
37 appear in the literature but are apparently available commercially. It was previously  
38 suggested<sup>[1]</sup> that 3-MeO-PCE (**3b**), and 3-MeO-PCPr (**3c**) had not been described in  
39 the scientific literature prior to their non-medical use. However, it was noticed that  
40 these were in fact described in a 1988 conference proceedings held by researchers  
41 at Eli Lilly. Both compounds showed NMDA receptor affinity and *in vivo* activity  
42 consistent with NMDA receptor antagonism.<sup>[32]</sup>  
43  
44

## 45 **Chromatography and mass spectrometry**

46  
47 Gas chromatography retention times and ion trap (IT) electron (EI) and chemical  
48 ionization (CI) mass spectral data (GC-IT-MS) are summarized in **Figures 3 and 4**.  
49 The proposed mechanism for EI-induced formation of base peak ions, which may  
50 have involved the loss of a propyl radical from the cyclohexyl component, was  
51 adapted from previously published work and is shown in **Figure 5A**<sup>[4]</sup>. The EI and CI  
52 mass spectra recorded for 3-MeO-PCE (**3b**) (Figure 3H1/H2) were comparable to  
53 previously published data<sup>[20]</sup> but some differences in relative abundance values were  
54 also visible, which might have been associated with the ion trap mass analyzer. For  
55 example, under the conditions used, the implementation of GC ion trap EI-MS  
56  
57  
58  
59  
60

1  
2  
3 frequently resulted in the formation of what appeared to be the protonated molecule  
4 instead of the  $M^{++}$  ion. In some cases, formation of the  $[M + H]^+$  ion formed the base  
5 peak similar to what was observed previously during the analysis of methoxetamine  
6 (MXE).<sup>[20,34]</sup> In the present study, it was noticed that  $[M + H]^+$  ions were particularly  
7 abundant in the EI-IT-MS spectra of the 2-methoxyphenyl substituted compounds  
8 (**2a**) – (**2c**) (Figure 3D1, 3E1 and 3F1). Self-ionization was not observed in any EI  
9 mass spectra recorded with a quadrupole mass analyzer where  $M^{++}$  ions were  
10 detectable in appreciable abundance (supplementary information).  
11  
12

13  
14 When inspecting the EI-IT mass spectra for potential differences between *N*-methyl  
15 substituted isomers (**2a**, **3a** and **4a**), it was observed that an ion at  $m/z$  189 was  
16 particularly abundant in the EI-IT mass spectrum of 4-MeO-PCMe (**4a**) (Figure 4J1)  
17 and that it was absent when using a quadrupole mass analyzer (supplemental data).  
18 Figure 5B shows a suggested mechanism that may account for this observation  
19 following the neutral loss of formaldehyde ( $CH_2O$ ) within the ion trap. The *ortho*- and  
20 *meta* isomers (**2a** and **3a**) (Figure 3D1 and 3G1) indicated a reduced formation of  
21  $m/z$  189 which may be explained by the proximity of the 2-OCH<sub>3</sub> group to the terminal  
22 methylene radical. Interestingly, the isomers 2-, 3-, and 4-MeO-PCE (**2b**, **3b** and **4b**)  
23 did not display this phenomenon, whereas the three *N*-propyl substituted PCPr  
24 counterparts (**2c**, **3c** and **4c**) formed this ion. Similarly, the most abundant  $m/z$  189  
25 species was observed in the spectrum of 4-MeO-PCPr (**4c**) (Figure 4L1), whereas it  
26 showed a relatively low abundance under quadrupole conditions (supplementary  
27 information). The CI-IT-MS spectra (Figures 3 and 4) yielded the expected  $[M + H]^+$   
28 ions and additional formation of an even-electron ion following the loss of the  
29 corresponding amine. In this case, the associated ions were formed at  $m/z$  165 (**1a**) –  
30 (**1c**),  $m/z$  189 (**2a**) – (**4c**) and  $m/z$  173 (**5a**) – (**5c**), respectively (Figure 5C) and were  
31 presumably similar to the species observed under electrospray ionization conditions  
32 (see below).  
33  
34  
35  
36

37 Interestingly, the CI-IT mass spectra recorded for 2-methoxyphenyl substituted  
38 substances (**2a**, **3a** and **4a**) differed from their isomeric representatives by the  
39 relative abundance of the  $m/z$  189 ion and the corresponding protonated molecules.  
40 The *meta*- and *para*-substituted compounds appeared to display a decrease in  
41 relative abundance of  $[M + H]^+$  relative to  $m/z$  189 in the order of 2-MeO-PCMe (**2a**)  
42 (Figure 3D2) > 3-MeO-PCMe (**3a**) (Figure 3G2) > 4-MeO-PCMe (**4a**) (Figure 4J2),  
43 respectively. A potential reason for what appeared to be increased stability of 2-MeO-  
44 PCMe (**2a**) may have been related to stabilization and increased charge distribution,  
45 thus, possibly rendering the protonated molecule more stable (Figure 5D). In  
46 addition, all CI-IT mass spectra obtained from the three 2-methoxyphenyl analogs  
47 also displayed an ion at  $m/z$  121 that was either less prominent or absent in the  
48 spectra of the *meta*- and *para* substituted analogs. Figure 5E depicts an attempt to  
49 rationalize its formation, which might require the presence of the 2-methoxyphenyl  
50 position.  
51  
52  
53  
54

55 Representative electrospray ionization (ESI) triple quadrupole (QqQ) tandem mass  
56 spectra and ion ratios for the 2-MeO-, 3-MeO-, and 4-MeO-PCE isomers (**2b**, **3b** and  
57 **4b**) following direct infusion are presented in Figure 6A–C. Collision-induced  
58 dissociation (CID) of the product ions gave primarily rise of two product ions at  $m/z$   
59  
60

189 and  $m/z$  121 that might be suitable for implementing the corresponding ion transitions for screening purposes. In case of 3-MeO-PCE (**3b**), these two main ions were also observed previously using a triple-quadrupole linear ion trap mass spectrometer. Correspondingly, the remaining ring-substituted PCMe (**2a**, **3a** and **4a**) and PCPr isomers (**2c**, **3c** and **4c**) also yielded the  $m/z$  189 and  $m/z$  121 ions (supplemental data). Examination of the QqQ spectra in Figure 6A–C also revealed the presence of a product ion at  $m/z$  81 in the spectra of 3-MeO-, and 4-MeO-PCE (**3b**, **4b**) that was absent in the QqQ tandem mass spectrum of 2-MeO-PCE (**2b**) (Figure 6A). Given that the tandem mass spectra were recorded under identical conditions and collision energies, it was tempting to consider the potential for differentiation between the three PCE isomers based on distinct ion ratios alone. The QqQ tandem mass spectrum of 3-MeO-PCE (**3b**) showed an increased abundance of the  $m/z$  81 species compared to 4-MeO-PCE (**4b**) (Figure 6B/6C). Interestingly, the differential formation of  $m/z$  81 was equally observed in the tandem mass spectra of the ring-substituted PCMe (**2a**, **3a** and **4a**) and PCPr isomers (**2c**, **3c** and **4c**) as well (supplemental data). The ultra high performance liquid chromatography (UHPLC) ESI quadrupole-time-of-flight (Q-TOF) tandem mass spectra for 3-MeO-, and 4-MeO-PCE (**2b**, **3b**) are shown in Figure 6D/7E. Due to extensive in-source CID of the protonated molecule of 4-MeO-PCE (**3b**) (Figure 6F), a tandem mass spectrum of the  $m/z$  189.12746 base peak was recorded as shown in Figure 6G. As observed in the QqQ tandem mass spectra of the 12 remaining *N*-alkyl arylcyclohexylamines (supplementary information), formation of the suggested cyclohexen-1-ylum ion at  $m/z$  81 was also frequently detected. The acquisition of high mass accuracy Q-TOF data was considered helpful for the proposal of suggested structural representations associated with  $m/z$  81,  $m/z$  121 and  $m/z$  189, respectively (Figure 7).

Implementation of the HPLC-DAD and UHPLC-Q-TOF-MS methods provided separation of the 2-MeO substituted *N*-alkyl arylcyclohexylamines (**2a–2c**) from their 3-MeO-, and 4-MeO counterparts (**3a–3c**) and (**4a–4c**), respectively. Co-elution, however, was observed for the latter two groups of *meta*- and *para*-substituted methoxyphenyl candidates (Figure 6 and supplementary information). Figure 8 shows the retention times and overlaid diode array spectra (DAD) obtained from PCE isomers (**2b**), (**3b**) and (**4b**), which demonstrated that the availability of full scan ultraviolet information facilitated differentiation between the co-eluting isomers. Similarly, the differentiation between the remaining 3-methoxy and 4-methoxyphenyl isomers (**3a/4a**) and (**3c/4c**) was also successful under DAD conditions and the corresponding spectra are shown as supplementary information. The use of HPLC-DAD has been increasingly helpful when applied to a number of investigations that investigated the presence and characterization of ring-substituted isomers.<sup>[6,35]</sup> In addition, the infrared spectra for all substances have been supplied as supplementary information, which confirmed that the isomeric 2-, 3- and 4-methoxy phenylcyclohexylamines could be differentiated, for example in the form of shifting wavenumbers associated 1,2-, 1,3-, and 1,4-disubstituted benzenes.<sup>[36]</sup> This was in agreement with shift changes observed with 2-, 3-, and 4-methylphenyl substituted PCP isomers.<sup>[37]</sup>

## Nuclear magnetic resonance spectroscopy

Chemical shifts were assigned using chemical shift position, splitting pattern,  $^{13}\text{C}$  polarization enhancement nurtured during attached nucleus testing (PENDANT) and 2-D techniques (HMQC, HMBC, COSY-90) similar to the approach taken previously for tertiary amine-based PCP and PCPy derivatives.<sup>[4]</sup> A representative example of an HMQC spectrum for 3-MeO-PCPr (**3c**) is shown in Figure 9. While some of the present compounds have been described for a range of investigations, limited information appeared available on the analytical properties including detailed NMR analysis. For example, NMR data were reported for thiophene compounds (**1a**) – (**1c**)<sup>[33,38]</sup> and 3-MeO-PCE (**3b**)<sup>[20]</sup> but without chemical shift assignments, which are provided here. The NMR data associated with the primary amine intermediates and a more detailed discussion of the NMR chemical shift behavior is presented in the supplemental section.

### Proton chemical shifts

All proton chemical shift values, multiplicities and assignments for arylcyclohexylamines (**1a**) – (**5c**) are summarized in Tables 1–3.

Identification of positional isomers is an important requirement of forensic identification. The three positional methoxyphenyl isomers could be readily distinguished by inspecting the downfield aromatic regions of the  $^1\text{H}$  proton spectra. Aromatic multiplicities exhibited  $^2\text{J}$  and  $^{3-4}\text{J}$  couplings. The multiplets linked to the *para*-substituted isomers were readily identified by a characteristic pair of doublets of multiplets that represented the aromatic protons due to additional splitting of the doublets by long-range couplings. The chemical shifts obtained from 2-, and 3-methoxyphenyl isomers were readily distinguishable in all equivalent *N*-alkyl pairs as a reflection of the position on the phenyl ring (Tables 1–3).

### Carbon chemical shifts

All chemical shift data are summarized in Tables 4–6.

$^{13}\text{C}$  chemical shifts were also useful in distinguishing the methoxyphenyl isomers. Due to the symmetry of *para*-substituted aryl rings, the 4-methoxyphenyl isomers displayed four separate aromatic  $^{13}\text{C}$  chemical shifts;  $\text{C}_1$ ,  $\text{C}_2\text{-C}_6$ ,  $\text{C}_3\text{-C}_5$ , and  $\text{C}_4$ . The 2- and 3-methoxyphenyl counterparts showed six distinct aromatic  $^{13}\text{C}$  chemical shifts. Another distinguishing feature was the  $\text{C}_1$  chemical shift value. In the spectra of 2- and 4-methoxyphenyl isomers, an upfield shift  $>10$  ppm was observed when compared to the *meta*-substituted series, presumably due to enhanced shielding and electron density from resonance contributions.

## Conclusion

Newly emerging psychoactive substances continue to remain a challenge for forensic scientists, clinicians and policy makers. The syntheses and comprehensive analytical



1  
2  
3 characterizations of 15 *N*-alkyl-arylcylohexylamines included a range of 'research  
4 chemical' analogues that have not yet been described in detail. It was also  
5 demonstrated that positional isomers could be differentiated using analytical  
6 techniques typically involved in forensic and clinical casework.  
7

## 8 9 References

10  
11  
12 [1] H. Morris, J. Wallach. From PCP to MXE: a comprehensive review of the non-  
13 medical use of dissociative drugs. *Drug Test. Anal.* **2014**, *6*, 614.  
14

15  
16 [2] G. McLaughlin, N. Morris, P.V. Kavanagh, J.D. Power, J. O'Brien, B. Talbot,  
17 S.P. Elliott, J. Wallach, K. Hoang, H. Morris, S.D. Brandt. Test purchase, synthesis  
18 and characterization of 2-methoxydiphenidine (MXP) and differentiation from its  
19 *meta*- and *para*-substituted isomers. *Drug Test. Anal.* **2015**, in press: doi:  
20 10.1002/dta.1800.  
21

22  
23 [3] J. Wallach, P.V. Kavanagh, G. McLaughlin, N. Morris, J.D. Power, S.P. Elliott,  
24 M.S. Mercier, D. Lodge, H. Morris, N.M. Dempster, S.D. Brandt. Preparation and  
25 characterization of the 'research chemical' diphenidine, its pyrrolidine analogue, and  
26 their 2,2-diphenylethyl isomers. *Drug Test. Anal.* **2015**, *7*, 358.  
27

28  
29 [4] J. Wallach, G. De Paoli, A. Adejare, S.D. Brandt. Preparation and analytical  
30 characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-  
31 phenylcyclohexyl)pyrrolidine (PCPy) analogues. *Drug Test. Anal.* **2014**, *6*, 633.  
32

33  
34 [5] The Misuse of Drugs Act 1971 (Amendment) Order 2013 No. 239. Available  
35 at: [http://www.legislation.gov.uk/ukxi/2013/239/pdfs/ukxi\\_20130239\\_en.pdf](http://www.legislation.gov.uk/ukxi/2013/239/pdfs/ukxi_20130239_en.pdf) [06 June  
36 2015].

37  
38 [6] S.P. Elliott, S.D. Brandt, J. Wallach, H. Morris, P.V. Kavanagh. First reported  
39 fatalities associated with the 'research chemical' 2-methoxydiphenidine. *J. Anal.*  
40 *Toxicol.* **2015**, *39*, 287.  
41

42  
43 [7] A. Helander, O. Beck, M. Bäckberg. Intoxications by the dissociative new  
44 psychoactive substances diphenidine and methoxphenidine. *Clin. Toxicol.* **2015**, *53*,  
45 446.

46  
47 [8] K.E. Hofer, C. Degrandi, D.M. Müller, U. Zürrer-Härdi, S. Wahl, C. Rauber-  
48 Lüthy, A. Ceschi. Acute toxicity associated with the recreational use of the novel  
49 dissociative psychoactive substance methoxphenidine. *Clin. Toxicol.* **2014**, *52*, 1288.  
50

51  
52 [9] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New  
53 psychoactive substances in Europe. An update from the EU Early Warning System  
54 (March 2015). Lisbon, 2015. Available at:  
55 [http://www.emcdda.europa.eu/attachements.cfm/att\\_235958\\_EN\\_TD0415135ENN.p](http://www.emcdda.europa.eu/attachements.cfm/att_235958_EN_TD0415135ENN.pdf)  
56 [df](http://www.emcdda.europa.eu/attachements.cfm/att_235958_EN_TD0415135ENN.pdf) [06 June 2015]  
57  
58  
59  
60

- 1  
2  
3 [10] S.D. Brandt, L.A. King, M. Evans-Brown. The new drug phenomenon. *Drug*  
4 *Test. Anal.* **2014**, 6, 587.  
5  
6 [11] Z. Ates-Alagoz, A. Adejare. NMDA receptor antagonists for treatment of  
7 depression. *Pharmaceuticals* **2013**, 6, 480.  
8  
9 [12] L.V. Kalia, S.K. Kalia, M.W. Salter. NMDA receptors in clinical neurology:  
10 excitatory times ahead. *Lancet Neurol.* **2008**, 7, 742.  
11  
12 [13] S.A. Lipton. Paradigm shift in neuroprotection by NMDA receptor blockade:  
13 memantine and beyond. *Nat. Rev. Drug Discov.* **2006**, 5, 160.  
14  
15 [14] K.W. Muir. Glutamate-based therapeutic approaches: clinical trials with  
16 NMDA antagonists. *Curr. Opin. Pharmacol.* **2006**, 6, 53.  
17  
18 [15] B.L. Roth, S. Gibbons, W. Arunotayanun, X.P. Huang, V. Setola, R. Treble, L.  
19 Iversen. The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of  
20 phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor.  
21 *PLoS One* **2013**, 8, e59334.  
22  
23 [16] C. Sauer, F.T. Peters, R.F. Staack, G. Fritschi, H.H. Maurer. New designer  
24 drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-  
25 phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and  
26 toxicological detection in rat urine using gas chromatographic/mass spectrometric  
27 techniques. *J. Mass Spectrom.* **2008**, 43, 305.  
28  
29 [17] P. Rösner, T. Junge, G. Fritschi, B. Klein. Neue synthetische Drogen:  
30 Piperazin-, Propicyclidin- und  $\alpha$ -Aminopropiophenonderivate. *Toxichem Krimtech*  
31 **1999**, 66, 81.  
32  
33 [18] C. Sauer, F.T. Peters, R.F. Staack, G. Fritschi, H.H. Maurer. New designer  
34 drug N-(1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA): Studies on its  
35 metabolism and toxicological detection in rat urine using gas chromatographic/mass  
36 spectrometric techniques. *J. Mass Spectrom.* **2006**, 41, 1014.  
37  
38 [19] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).  
39 EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision  
40 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on  
41 the information exchange, risk-assessment and control of new psychoactive  
42 substances. Lisbon, **2011**. Available at:  
43 [http://www.emcdda.europa.eu/attachements.cfm/att\\_132857\\_EN EMCDDA-Europol](http://www.emcdda.europa.eu/attachements.cfm/att_132857_EN EMCDDA-Europol Annual Report 2010A.pdf)  
44 [Annual Report 2010A.pdf](http://www.emcdda.europa.eu/attachements.cfm/att_132857_EN EMCDDA-Europol Annual Report 2010A.pdf) [06 June 2015].  
45  
46 [20] G. De Paoli, S.D. Brandt, J. Wallach, R.P. Archer, D.J. Pounder. From the  
47 street to the laboratory: analytical profiles of methoxetamine, 3-methoxyeticyclidine  
48 and 3-methoxyphencyclidine and their determination in three biological matrices. *J.*  
49 *Anal. Toxicol.* **2013**, 37, 277.  
50  
51 [21] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New  
52 drugs in Europe, 2012. EMCDDA–Europol 2012 Annual Report on the  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 implementation of Council Decision 2005/387/JHA. Lisbon. **2013**. Available at:  
4 [http://www.emcdda.europa.eu/attachements.cfm/att\\_212366\\_EN\\_EMCDDE-Europol](http://www.emcdda.europa.eu/attachements.cfm/att_212366_EN_EMCDDE-Europol)  
5 [2012 Annual Report\\_final.pdf](http://www.emcdda.europa.eu/attachements.cfm/att_212366_EN_EMCDDE-Europol) [06 June 2015].  
6

7  
8 [22] R. F. Parcell. Heterocyclic compounds and methods for producing the same.  
9 Patent US2921076A. Parke, Davis & Co. **1960**.

10  
11 [23] A. Thurkauf, B. de Costa, S. Yamaguchi, M.V. Mattson, A.E. Jacobson, K.C.  
12 Rice, M.A. Rogawski. Synthesis and anticonvulsant activity of 1-  
13 phenylcyclohexylamine analogs. *J. Med. Chem.* **1990**, 33, 1452.  
14

15  
16 [24] V.H. Maddox, E.F. Godefroi, R.F. Parcell. The synthesis of phencyclidine and  
17 other 1-arylcyclohexylamines. *J. Med. Chem.* **1965**, 8, 230.  
18

19  
20 [25] S.P. Elliott, S.D. Brandt, S. Freeman, R.P. Archer. AMT (3-(2-  
21 aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): an analytical challenge and  
22 implications for forensic analysis. *Drug Test. Anal.* **2013**, 5, 196.  
23

24  
25 [26] Y.N.A. Soh, S. Elliott. An investigation of the stability of emerging new  
26 psychoactive substances. *Drug Test. Anal.* **2013**, 6, 696.  
27

28  
29 [27] A.C. Allen, J. Robles, W. Dovenski, S. Calderon. PCP: a review of synthetic  
30 methods for forensic clandestine investigation. *Forensic Sci. Int.* **1993**, 61, 85.  
31

32  
33 [28] P. Geneste, P. Herrmann, J.M. Kamenka, A. Pons. Nouvelles voies d'accès  
34 aux isomères des phényl-1-cyclohexylamines substituées au cyclohexane. *Bull. Soc.*  
35 *Chim. France* **1975**, 7, 1619.  
36

37  
38 [29] M. Rogawski, A. Thurkauf, K. Rice, A. Jacobsen, J. French-Mullen,  
39 Anticonvulsant activity of phencyclidine analogs: structural modifications resulting in  
40 enhanced seizure protection relative to motor side effects. In *Frontiers in excitatory*  
41 *amino acid research: proceedings of an international symposium "Excitatory Acids*  
42 *'88," Manaus, Amazonas, Brazil, March 28-April 2, 1988*, (Ed.: L. Turski, J. Lehmann,  
43 E.A. Cavalheiro), Liss, New York, **1988**, pp. 227.  
44

45  
46 [30] S.O. Casalotti, A.P. Kozikowski, A. Fauq, W. Tückmantel, K.E. Krueger.  
47 Design of an irreversible affinity ligand for the phencyclidine recognition site on N-  
48 methyl-D-aspartate-type glutamate receptors. *J. Pharmacol. Exp. Ther.* **1992**, 260,  
49 21.  
50

51  
52 [31] V. John, R. Hom, J. Sealy, J. Aquino, G. Probst, J. Tung, L. Fang. Methods of  
53 treatment of amyloidosis using aspartyl-protease inhibitors. Patent.  
54 WO2005070407A1, Elan Pharmaceuticals, Inc. **2005**.  
55

56  
57 [32] J.K. Reel, J.D. Leander, L.G. Mendelsohn, D.D. Schoepp, P.L. Ornstein, D.A.  
58 Evrard, R.B. Hermann, D.M. Zimmerman, The search for a PCP antagonist:  
59 synthesis and characterization of novel arylcyclohexylamine derivatives. In *Sigma*  
60 *and Phencyclidine-Like Compounds as Molecular Probes in Biology*, (Ed.: E.F.  
Domino, J.M. Kamenka), Npp Books, Ann Arbor, MI, **1988**, pp. 27.

- 1  
2  
3 [33] X. Ouyang, J. Mukherjee, Z.-Y. Yang. Synthesis, radiosynthesis, and  
4 biological evaluation of fluorinated thienylcyclohexyl piperidine derivatives as  
5 potential radiotracers for the NMDA receptor-linked calcium ionophore. *Nucl. Med.*  
6 *Biol.* **1996**, 23, 315.  
7  
8 [34] A.D. Westwell, A. Hutchings, D.G.E. Caldicott. The identification and chemical  
9 characterization of a new arylcyclohexylamine, methoxetamine, using a novel  
10 Emergency Department toxicosurveillance tool. *Drug Test. Anal.* **2013**, 5, 203.  
11  
12 [35] S.D. Brandt, S.P. Elliott, P.V. Kavanagh, N.M. Dempster, M.R. Meyer, H.H.  
13 Maurer, D.E. Nichols. Analytical characterization of bioactive N-benzyl-substituted  
14 phenethylamines and 5-methoxytryptamines. *Rapid Commun. Mass Spectrom.* **2015**,  
15 29, 573.  
16  
17 [36] D.H. Williams, I. Fleming, *Spectroscopic Methods in Organic Chemistry, Fifth*  
18 *Edition*, McGraw-Hill, Berkshire, UK, **1995**.  
19  
20 [37] B.A. Lodge, R. Duhaime, J. Zamecnik, P. Macmurray, R. Brousseau. New  
21 street analogs of phencyclidine. *Forensic Sci. Int.* **1992**, 55, 13.  
22  
23 [38] J. M. Kamenka, J. Hamon, J. Vignon. Phencyclidine derivatives, preparation  
24 method and pharmaceutical compositions containing same. Patent. US6342511B1.  
25 Société de Conseils de Recherches et d'Applications Scientifiques. **2002**.  
26  
27  
28  
29  
30

### Figure captions

31  
32  
33 **Figure 1. Phencyclidine (PCP) and other representative arylcyclohexylamine and 1,2-**  
34 **diphenylethylamine examples associated with the recreational 'research chemicals'**  
35 **market.**  
36

37  
38 **Figure 2. A: Fifteen N-alkyl-aryl-cyclohexylamines subjected to synthesis and**  
39 **analytical characterizations. B: Synthetic routes employed for the preparation of (1a)**  
40 **– (5c)**  
41

42  
43 Figure 3. Gas chromatography retention times and ion trap (IT) mass spectra  
44 obtained in electron (EI) and chemical ionization (CI) mode.  
45

46  
47 Figure 4. Gas chromatography retention times and ion trap (IT) mass spectra  
48 obtained in electron (EI) and chemical ionization (CI) mode.  
49

50  
51 Figure 5. Suggested key ions following mass spectral detection under EI and CI  
52 conditions.  
53



54  
55 Figure 6. A-C: Electrospray ionization triple quadrupole mass spectra of three  
56 positional N-ethyl-1-phenylcyclohexan-1-amine (PCE) isomers. D-G. Ultra-high  
57 performance liquid chromatography quadrupole time of flight tandem mass spectra.  
58  
59  
60

1  
2  
3 Figure 7. Suggested key ions following mass spectral detection under electrospray  
4 ionization conditions.  
5

6  
7 Figure 8. Ultraviolet full scan spectra of *N*-ethyl-1-phenylcyclohexan-1-amine (PCE)  
8 isomers by high-performance liquid chromatography coupled to diode array detection.  
9

10 Figure 9. Heteronuclear single quantum coherence spectrum (HSQC) of 3-MeO-  
11 PCPr.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






For Peer Review



27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. Phencyclidine (PCP) and other representative arylcyclohexylamine and 1,2-diphenylethylamine examples associated with the recreational 'research chemicals' market.  
118x69mm (300 x 300 DPI)

A

(1a): R = CH<sub>3</sub> (TCMe)(1b): R = CH<sub>2</sub>CH<sub>3</sub> (TCE)(1c): R = CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> (TCPPr)(2a): R = CH<sub>3</sub> (2-MeO-PCMe)(2b): R = CH<sub>2</sub>CH<sub>3</sub> (2-MeO-PCE)(2c): R = CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> (2-MeO-PCPr)(3a): R = CH<sub>3</sub> (3-MeO-PCMe)(3b): R = CH<sub>2</sub>CH<sub>3</sub> (3-MeO-PCE)(3c): R = CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> (3-MeO-PCPr)(4a): R = CH<sub>3</sub> (4-MeO-PCMe)(4b): R = CH<sub>2</sub>CH<sub>3</sub> (4-MeO-PCE)(4c): R = CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> (4-MeO-PCPr)(5a): R = CH<sub>3</sub> (3-Me-PCMe)(5b): R = CH<sub>2</sub>CH<sub>3</sub> (3-Me-PCE)(5c): R = CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> (3-Me-PCPr)

B














Figure 2. A: Fifteen N-alkyl-aryl cyclohexylamines subjected to synthesis and analytical characterizations. B: Synthetic routes employed for the preparation of (1a) - (5c)  
207x225mm (300 x 300 DPI)







1  
2  
3  
4  
5  
6  
7





$R^1 = 2-, 3-, 4-OCH_3; R^2 = CH_3: m/z 176$  (**2a, 3a, 4a**)  
 $R^1 = 2-, 3-, 4-OCH_3; R^2 = C_2H_5: m/z 190$  (**2b, 3b, 4b**)  
 $R^1 = 2-, 3-, 4-OCH_3; R^2 = C_3H_7: m/z 204$  (**2c, 3c, 4c**)




$R = CH_3: m/z 152$  (**1a**)  
 $R = C_2H_5: m/z 166$  (**1b**)  
 $R = C_3H_7: m/z 180$  (**1c**)

$R = CH_3: m/z 160$  (**5a**)  
 $R = C_2H_5: m/z 174$  (**5b**)  
 $R = C_3H_7: m/z 188$  (**5c**)




$m/z 189$

2-, 3-, 4-MeO-PCMe (**2a, 3a, 4a**)  
 2-, 3-, 4-MeO-PCE (**2b, 3b, 4b**)  
 2-, 3-, 4-MeO-PCPr (**2c, 3c, 4c**)





$m/z 165$

TCMe (**1a**)  
 TCE (**1b**)  
 TCPPr (**1c**)






$m/z 173$


3-Me-PCMe (**5a**)  
 3-Me-PCE (**5b**)  
 3-Me-PCPr (**5c**)




Drug Testing and Analysis




27 ESI Product Ion (2.303 min) Frag=110.0V CID@18.2 (234.18517[z=1] -> \*\*) PCP 2b-MSMS.d




38 ESI Product Ion (2.139 min) Frag=110.0V CID@18.2 (234.18520[z=1] -> \*\*) PCP 3b-MSMS.d




47 ESI Scan (2.160 min) Frag=130.0V PCP 4b-MS.d



56 ESI Product Ion (2.163 min) Frag=110.0V CID@15.5 (189.12746[z=1] -> \*\*) PCP 4b-MSMS.d





20 R = CH<sub>3</sub>:  $m/z$  220



21 R = C<sub>2</sub>H<sub>5</sub>:  $m/z$  234

22 R = C<sub>3</sub>H<sub>7</sub>:  $m/z$  248

23  
24  
25 -, 4-MeO-PCMe (**2a**, **3a**, **4a**)


26 -, 4-MeO-PCE (**2b**, **3b**, **4b**)

27 -, 4-MeO-PCPr (**2c**, **3c**, **4c**)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review






Table 1. 400 MHz <sup>1</sup>H NMR spectra of HCl salts in CDCl<sub>3</sub>.

Proton	TCMe (1a)	2-MeO-PCMe (2a)	3-MeO-PCMe (3a)	4-MeO-PCMe (4a)	3-Me-PCMe (5a)
H <sub>2,6</sub>	2.59 d (13.0 Hz, 2H <sub>eq</sub> ) 2.32–2.18 m (2H <sub>ax</sub> )	2.67 d (12.7 Hz, 2H <sub>eq</sub> ) 2.51–2.24 m (2H <sub>ax</sub> )	2.61 d (12.9 Hz, 2H <sub>eq</sub> ) 2.41–2.12 m (2H <sub>ax</sub> )	2.62 d (12.8 Hz, 2H <sub>eq</sub> ) 2.28–2.15 m (2H <sub>ax</sub> )	2.62 d (13.2 Hz, 2H <sub>eq</sub> ) 2.33–2.19 m (2H <sub>ax</sub> )
H <sub>3,5</sub>	1.92–1.73 m (2H <sub>eq</sub> ) 1.60–1.34 m (2H <sub>ax</sub> )	1.99–1.80 m (2H <sub>eq</sub> ) 1.46–1.27 m (2H <sub>ax</sub> )	2.03–1.76 m (2H <sub>eq</sub> ) 1.45–1.31 m (2H <sub>ax</sub> )	1.90–1.75 m (2H <sub>eq</sub> ) 1.35 m (2H <sub>ax</sub> )	1.93–1.77 m (2H <sub>eq</sub> ) 1.38 qt (13.4, 3.4 Hz, 2H <sub>ax</sub> )
H <sub>4</sub>	1.66–1.54 m (1H <sub>eq</sub> ) 1.60–1.34 m (1H <sub>ax</sub> )	1.71–1.56 m (1H <sub>eq</sub> ) 1.53 qt (11.7, 3.8 Hz, 1H <sub>ax</sub> )	1.64–1.45 m (1H <sub>eq</sub> ) 1.52 qt (12.6, 3.6 Hz, 1H <sub>ax</sub> )	1.63–1.52 m (1H <sub>eq</sub> ) 1.48 qt (12.8, 3.7 Hz, 1H <sub>ax</sub> )	1.64–1.45 m (2H)
H <sub>1</sub>	—	—	—	—	—
H <sub>2</sub>	7.42 dd (3.7, 1.2 Hz)	—	7.37 t (2.2 Hz)	7.64 dm (8.9 Hz)	7.57 s
H <sub>3</sub>	7.09 dd (5.1, 3.7 Hz)	6.99 dd (8.0, 1.0 Hz)	—	6.98 dm (8.9 Hz)	—
H <sub>4</sub>	7.38 dd (5.1, 1.2 Hz)	7.42–7.35 m	6.91 ddd (8.3, 2.5, 1.0 Hz)	—	7.50 d (7.8 Hz)
H <sub>5</sub>	—	7.03 td (7.6, 1.2 Hz)	7.34 t (8.0 Hz)	6.98 dm (8.9 Hz)	7.34 t (7.8 Hz)
H <sub>6</sub>	—	7.42–7.35 m	7.22 ddd (7.8, 2.0, 0.9 Hz)	7.64 dm (8.9 Hz)	7.18 d (7.8 Hz)
H <sub>α</sub>	2.34 s (CH <sub>3</sub> )	2.32 s (CH <sub>3</sub> )	2.23 s (CH <sub>3</sub> )	2.23 s (CH <sub>3</sub> )	2.23 s (CH <sub>3</sub> )
H <sub>β</sub>	—	—	—	—	—
H <sub>γ</sub>	—	—	—	—	—
H <sub>c</sub>	—	4.04 s (OCH <sub>3</sub> )	3.90 s (OCH <sub>3</sub> )	3.83 s (OCH <sub>3</sub> )	2.62 s (CH <sub>3</sub> )
NH <sup>+</sup>	9.73 s (NH <sub>2</sub> <sup>+</sup> )	9.30 s (NH <sub>2</sub> <sup>+</sup> )	9.60 s (NH <sub>2</sub> <sup>+</sup> )	9.53 s (NH <sub>2</sub> <sup>+</sup> )	9.58 s (NH <sub>2</sub> <sup>+</sup> )

\* b = broad; d = doublet; m = multiplet; s = singlet; triplet; q = quartet; quint = quintet; sex = sextet

Table 2. 400 MHz <sup>1</sup>H NMR spectra of HCl salts in CDCl<sub>3</sub>.

Proton	TCE (1b)	2-MeO-PCE (2b)	3-MeO-PCE (3b)	4-MeO-PCE (4b)	3-Me-PCE (5b)
H <sub>2,6</sub>	2.73 d (13.0 Hz, 2H <sub>eq</sub> ) 2.39 td (12.5, 3.7 Hz, 2H <sub>ax</sub> )	2.61 d (12.7 Hz, 2H <sub>eq</sub> ) 2.45 td (12.6, 3.9 Hz, 2H <sub>ax</sub> )	2.77 d (13.0 Hz, 2H <sub>eq</sub> ) 2.34 td (13.3, 3.7 Hz, 2H <sub>ax</sub> )	2.80 d (12.6 Hz, 2H <sub>eq</sub> ) 2.33 td (13.1, 3.4 Hz, 2H <sub>ax</sub> )	2.81 d (12.6 Hz, 2H <sub>eq</sub> ) 2.35 td (13.1, 3.6 Hz, 2H <sub>ax</sub> )
H <sub>3,5</sub>	1.86–1.72 m (2H <sub>eq</sub> ) 1.54–1.34 m (2H <sub>ax</sub> )	1.94–1.82 m (2H <sub>eq</sub> ) 1.46–1.28 m (2H <sub>ax</sub> )	1.88–1.72 m (2H <sub>eq</sub> ) 1.35 qt (12.8, 3.3 Hz, 2H <sub>ax</sub> )	1.89–1.70 m (2H <sub>eq</sub> ) 1.29 qt (12.9, 3.4 Hz, 2H <sub>ax</sub> )	1.87–1.72 m (2H <sub>eq</sub> ) 1.31 qt (13.0, 3.2 Hz, 2H <sub>ax</sub> )
H <sub>4</sub>	1.69–1.53 m (1H <sub>eq</sub> ) 1.54–1.34 m (1H <sub>ax</sub> )	1.65–1.57 m (1H <sub>eq</sub> ) 1.52 qt (11.7, 4.1 Hz, 1H <sub>ax</sub> )	1.67–1.56 m (1H <sub>eq</sub> ) 1.48 qt (12.4, 3.8 Hz, 1H <sub>ax</sub> )	1.66–1.54 m (1H <sub>eq</sub> ) 1.48 qt (12.8, 3.8 Hz, 1H <sub>ax</sub> )	1.70–1.54 m (1H <sub>eq</sub> ) 1.47 qt (12.4, 3.8 Hz, 1H <sub>ax</sub> )
H <sub>1</sub>	—	—	—	—	—
H <sub>2</sub>	7.48 dd (3.8, 1.1 Hz)	—	7.47 t (2.1 Hz)	7.71 dm (8.9 Hz)	7.65 s
H <sub>3</sub>	7.10 dd (5.2, 3.6 Hz)	7.01 dd (8.0, 0.9 Hz)	—	6.99 dm (8.9 Hz)	—
H <sub>4</sub>	7.39 dd (5.2, 1.1 Hz)	7.40–7.35 m	6.92 ddd (8.1, 2.5, 1.0 Hz)	—	7.57 d (7.9 Hz)
H <sub>5</sub>	—	7.06 td (7.6, 1.1 Hz)	7.36 t (8.0 Hz)	6.99 dm (8.9 Hz)	7.35 t (7.7 Hz)
H <sub>6</sub>	—	7.40–7.35 m	7.30 d (7.7 Hz)	7.71 dm (8.9 Hz)	7.18 d (7.6 Hz)
H <sub>α</sub>	2.80–2.68 m (CH <sub>2</sub> )	2.69 bs (CH <sub>2</sub> )	2.69–2.53 m (CH <sub>2</sub> )	2.68–2.53 m (CH <sub>2</sub> )	2.67–2.51 m (CH <sub>2</sub> )
H <sub>β</sub>	1.42 t (7.3 Hz, CH <sub>3</sub> )	1.36 t (7.3 Hz, CH <sub>3</sub> )	1.38 t (7.3 Hz, CH <sub>3</sub> )	1.29 t (7.3 Hz, CH <sub>3</sub> )	1.38 t (7.3 Hz, CH <sub>3</sub> )
H <sub>γ</sub>	—	—	—	—	—
H <sub>c</sub>	—	4.01 s (OCH <sub>3</sub> )	3.91 s (OCH <sub>3</sub> )	3.83 s (OCH <sub>3</sub> )	2.43 s (CH <sub>3</sub> )
NH <sup>+</sup>	9.63 s (NH <sub>2</sub> <sup>+</sup> )	9.20 bs (NH <sub>2</sub> <sup>+</sup> )	9.53 s (NH <sub>2</sub> <sup>+</sup> )	9.45 s (NH <sub>2</sub> <sup>+</sup> )	9.50 s (NH <sub>2</sub> <sup>+</sup> )

\* b = broad; d = doublet; m = multiplet; s = singlet; triplet; q = quartet; quint = quintet; sex = sextet.



Table 3. 400 MHz <sup>1</sup>H NMR spectra of HCl salts in CDCl<sub>3</sub>.

Proton	TCPr (1c)	2-MeO-PCPr (2c)	3-MeO-PCPr (3c)	4-MeO-PCPr (4c)	3-Me-PCPr (5c)
H <sub>2,6</sub>	2.73 d (12.7 Hz, 2H <sub>eq</sub> ) 2.47–2.32 m (2H <sub>ax</sub> )	2.65–2.50 m (2H <sub>eq</sub> ) 2.45 td (13.0, 3.6 Hz, 2H <sub>ax</sub> )	2.78 d (12.6 Hz, 2H <sub>eq</sub> ) 2.35 td (13.0, 3.5 Hz, 2H <sub>ax</sub> )	2.79 d (12.5 Hz, 2H <sub>eq</sub> ) 2.34 td (12.9, 3.5 Hz, 2H <sub>ax</sub> )	2.81 d (12.6 Hz, 2H <sub>eq</sub> ) 2.35 td (13.0, 3.5 Hz, 2H <sub>ax</sub> )
H <sub>3,5</sub>	1.85–1.74 m (2H <sub>eq</sub> ) 1.53–1.37 m (2H <sub>ax</sub> )	1.93–1.76 m (2H <sub>eq</sub> ) 1.46–1.19 m (2H <sub>ax</sub> )	1.83–1.71 m (2H <sub>eq</sub> ) 1.34 qt (13.0, 3.5 Hz, 2H <sub>ax</sub> )	1.81–1.69 m (2H <sub>eq</sub> ) 1.29 qt (13.2, 3.4 Hz, 2H <sub>ax</sub> )	1.82–1.70 m (2H <sub>eq</sub> ) 1.29 qt (12.7, 3.5 Hz, 2H <sub>ax</sub> )
H <sub>4</sub>	1.66–1.56 m (1H <sub>eq</sub> ) 1.53–1.37 m (1H <sub>ax</sub> )	1.66–1.57 m (1H <sub>eq</sub> ) 1.51 qt (12.3, 3.7 Hz, 1H <sub>ax</sub> )	1.70–1.53 m (1H <sub>eq</sub> ) 1.46 qt (12.5, 3.7 Hz, 1H <sub>ax</sub> )	1.65–1.53 m (1H <sub>eq</sub> ) 1.47 qt (12.6, 3.8 Hz, 1H <sub>ax</sub> )	1.64–1.54 m (1H <sub>eq</sub> ) 1.48 qt (12.8, 3.7 Hz, 1H <sub>ax</sub> )
H <sub>1</sub>	–	–	–	–	–
H <sub>2</sub>	7.48 dd (3.6, 1.4 Hz)	–	7.47 t (2.1 Hz)	7.71 dm (8.9 Hz)	7.66 s
H <sub>3</sub>	7.10 dd (5.1, 3.5 Hz)	7.01 dd (8.8, 1.2 Hz)	–	6.99 dm (8.9 Hz)	–
H <sub>4</sub>	7.39 dd (5.2, 1.2 Hz)	7.45–7.37 m	6.92 ddd (8.0, 2.3, 0.9 Hz)	–	7.56 d (8.0 Hz)
H <sub>5</sub>	–	7.06 td (7.6, 1.2 Hz)	7.36 t (8.0 Hz)	6.99 dm (8.9 Hz)	7.35 t (7.7 Hz)
H <sub>6</sub>	–	7.45–7.37 m	7.32–7.25 m	7.71 dm (8.9 Hz)	7.19 d (7.7 Hz)
H <sub>α</sub>	2.66–2.51 m (CH <sub>2</sub> )	2.65–2.50 m (CH <sub>2</sub> )	2.50–2.40 m (CH <sub>2</sub> )	2.50–2.39 m (CH <sub>2</sub> )	2.46–2.40 m (CH <sub>2</sub> )
H <sub>β</sub>	1.98–1.83 m (CH <sub>2</sub> )	1.93–1.76 m (CH <sub>2</sub> )	1.97–1.83 m (CH <sub>2</sub> )	1.96–1.81 m (CH <sub>2</sub> )	1.96–1.82 m (CH <sub>2</sub> )
H <sub>γ</sub>	0.84 t (7.5 Hz, CH <sub>3</sub> )	0.83 t (7.4 Hz, CH <sub>3</sub> )	0.80 t (7.4 Hz, CH <sub>3</sub> )	0.79 t (7.4 Hz, CH <sub>3</sub> )	0.79 t (7.7 Hz, CH <sub>3</sub> )
H <sub>c</sub>	–	3.98 s (OCH <sub>3</sub> )	3.91 s (OCH <sub>3</sub> )	3.84 s (OCH <sub>3</sub> )	2.43 s (CH <sub>3</sub> )
NH <sup>+</sup>	9.58 s (NH <sub>2</sub> <sup>+</sup> )	9.00 bs (NH <sub>2</sub> <sup>+</sup> )	9.47 s (NH <sub>2</sub> <sup>+</sup> )	9.38 s (NH <sub>2</sub> <sup>+</sup> )	9.44 s (NH <sub>2</sub> <sup>+</sup> )

\* b = broad; d = doublet; m = multiplet; s = singlet; triplet; q = quartet; quint = quintet; sex = sextet.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 4. 100 MHz  $^{13}\text{C}$  NMR spectra of HCl salts in  $\text{CDCl}_3$ .

Carbon	TCMe (1a)	2-MeO-PCMe (2a)	3-MeO-PCMe (3a)	4-MeO-PCMe (4a)	3-Me-PCMe (5a)
C <sub>1</sub>	61.95	64.08	63.64	63.26	63.49
C <sub>2,6</sub>	34.68	32.42	33.28	33.21	33.16
C <sub>3,5</sub>	22.12	22.74	22.03	21.99	22.02
C <sub>4</sub>	24.66	25.06	24.96	25.90	25.01
C <sub>1'</sub>	139.71	123.20	136.91	126.68	135.14
C <sub>2'</sub>	128.66	157.42	112.93	129.43	128.56
C <sub>3'</sub>	127.81	111.59	160.48	114.44	139.02
C <sub>4'</sub>	127.03	130.36	115.14	159.68	124.99
C <sub>5'</sub>	–	120.69	129.98	114.44	129.00
C <sub>6'</sub>	–	130.48	120.09	129.43	129.57
$\alpha$	25.97	26.95	26.10	25.03	26.09
$\beta$	–	–	–	–	–
$\gamma$	–	–	–	–	–
C <sub>c</sub>	–	55.65	55.65	55.24	21.61

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Carbon	TCE ( <b>1b</b> )	2-MeO-PCE ( <b>2b</b> )	3-MeO-PCE ( <b>3b</b> )	4-MeO-PCE ( <b>4b</b> )	3-Me-PCE ( <b>5b</b> )
$\text{C}_1$	62.60	64.81	64.30	63.94	64.15
$\text{C}_{2,6}$	34.93	32.54	33.44	33.39	33.33
$\text{C}_{3,5}$	22.36	22.76	22.30	22.23	22.29
$\text{C}_4$	24.71	24.92	25.05	25.13	25.09
$\text{C}_{1'}$	139.98	123.96	137.01	126.86	135.19
$\text{C}_{2'}$	128.88	157.06	113.26	129.72	128.83
$\text{C}_{3'}$	127.86	111.94	160.42	114.43	138.99
$\text{C}_{4'}$	126.98	130.50	115.01	159.61	125.31
$\text{C}_{5'}$	–	121.23	129.94	114.43	128.98
$\text{C}_{6'}$	–	130.37	120.41	129.72	129.47
$\alpha$	36.73	37.25	36.79	36.58	36.76
$\beta$	11.95	12.84	12.07	11.98	12.01
$\gamma$	–	–	–	–	–
$\text{C}_c$	–	55.57	55.72	55.23	21.66

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 6. 100 MHz  $^{13}\text{C}$  NMR spectra of HCl salts in  $\text{CDCl}_3$ .

Carbon	TCPr ( <b>1c</b> )	2-MeO-PCPr ( <b>2c</b> )	3-MeO-PCPr ( <b>3c</b> )	4-MeO-PCPr ( <b>4c</b> )	3-Me-PCPr ( <b>5c</b> )
$\text{C}_1$	62.73	64.84	64.42	64.05	64.26
$\text{C}_{2,6}$	34.89	32.32	33.21	33.36	33.29
$\text{C}_{3,5}$	22.40	22.79	22.34	22.22	22.32
$\text{C}_4$	24.71	24.86	25.05	25.12	25.08
$\text{C}_{1'}$	139.98	123.92	137.02	126.88	135.20
$\text{C}_{2'}$	128.91	156.81	113.23	129.74	128.85
$\text{C}_{3'}$	127.85	111.93	160.45	114.41	139.00
$\text{C}_{4'}$	126.98	130.57	115.05	159.59	125.33
$\text{C}_{5'}$	–	121.36	129.92	114.41	128.94
$\text{C}_{6'}$	–	130.41	120.44	129.74	129.48
$\alpha$	43.29	43.64	43.35	43.17	43.31
$\beta$	19.95	20.30	20.07	19.97	20.00
$\gamma$	11.49	11.05	11.45	11.45	11.44
$\text{C}_c$	–	55.53	55.74	55.22	21.67